Comprehensive Study Guide to Metabotropic Receptors and GPCR Signaling

Fundamentals of Ionotropic vs. Metabotropic Neurotransmission

• Structural and Functional Classification of Receptors:
  • Ionotropic Receptors (Ligand-Gated Ion Channels): Integral membrane proteins that combine neurotransmitter-binding sites and an ion channel pore within the same multimeric complex. Neurotransmitter binding directly opens the channel pore, permitting rapid flux of specific ions across the plasma membrane down their electrochemical gradients.
  • Metabotropic Receptors (G-Protein Coupled Receptors - GPCRs): Monomeric or dimeric seven-transmembrane-domain receptors that do not contain an intrinsic channel pore. Instead, neurotransmitter binding activates an intracellular guanine nucleotide-binding regulatory protein (heterotrimeric G-protein), which initiates intracellular enzymatic cascades and second-messenger systems to regulate downstream ion channels and effectors.

• Summary of Ionotropic Receptor Superfamilies:
  • Cys-Loop / Pentameric Ionotropic Receptors:
    • Quaternary Structure: Composed of $5$ individual protein subunits assembled symmetrically around a central aqueous ion-conducting pore.
    • Transmembrane Architecture: Each subunit contains $4$ alpha-helical transmembrane domains ($M1$, $M2$, $M3$, and $M4$), with both the amino ($N$) terminus and carboxyl ($C$) terminus residing in the extracellular space.
    • Representative Members and Permeability:
      • Nicotinic Acetylcholine Receptors ($nAChRs$): Cation-permeable, conducting both $Na^+$ and $K^+$.
      • $GABA_A$ Receptors: Anion-permeable, selective for $Cl^-$.
      • Glycine Receptors: Anion-permeable, selective for $Cl^-$.

*   **Tetrameric Ionotropic Glutamate Receptors ($iGluRs$):**
    *   **Quaternary Structure:** Composed of $4$ individual subunits arranged as a tetramer.
    *   **Transmembrane Architecture:** Each subunit contains $3$ complete transmembrane alpha-helices and a re-entrant pore loop. Subunits exhibit an extracellular amino-terminal domain ($ATD$), a bi-lobed ligand-binding domain ($LBD$), a transmembrane domain ($TMD$), and an intracellular carboxyl-terminal domain ($CTD$).
    *   **Representative Members and Permeability:**
        *   **$GluA$ (AMPA) and $GluK$ (Kainate) Receptors:** Conduct primarily $Na^+$ and $K^+$. Permeability to $Ca^{2+}$ is regulated by post-transcriptional RNA editing (specifically the $Q/R$ site in AMPA receptor subunit $GluA2$).
        *   **$GluN$ (NMDA) Receptors:** Highly permeable to both $Na^+$ and $Ca^{2+}$. At resting membrane potentials, NMDA receptor channels are blocked by extracellular magnesium ($Mg^{2+}$), requiring membrane depolarization to relieve the voltage-dependent $Mg^{2+}$ block.

• Synaptic Integration and State-Dependent Postsynaptic Potentials:
  • The directional consequence of activating an ionotropic receptor—generating an Excitatory Postsynaptic Potential ($EPSP$) versus an Inhibitory Postsynaptic Potential ($IPSP$)—is determined entirely by the relationship between the membrane potential ($V_m$) and the reversal potential ($E_{rev}$) for the conducting ions.
  • Excitatory Synapses (Glutamate and Acetylcholine via $nAChRs$):
    • These receptors permit non-selective flow of cations ($Na^+$ and $K^+$).
    • The combined reversal potential ($E_{rev}$) is approximately $0\,mV$.
    • Because normal resting potential ($V_{rest} \approx -60\,mV$) is far more negative than $0\,mV$, receptor activation causes a net inward current that depolarizes the postsynaptic membrane toward $0\,mV$. If the threshold ($\approx -40\,mV$) is exceeded, an action potential is triggered ($E_{Na} \approx +50\,mV$, $E_K \approx -110\,mV$).
  • Inhibitory Synapses (GABA via $GABA_A$ and Glycine):
    • These receptors gate selective chloride channels ($Cl^-$).
    • The reversal potential ($E_{rev}$) for $Cl^-$ is approximately $-70\,mV$.
    • If the postsynaptic membrane potential is depolarized relative to $-70\,mV$ (e.g., at $V_{rest} = -60\,mV$), activation of these receptors drives $Cl^-$ influx, hyperpolarizing the membrane toward $-70\,mV$ and generating an $IPSP$ that moves the potential further away from the action potential threshold ($-40\,mV$).

• Systematic Distribution of Neurotransmitter Receptor Types:
  • Exclusively or Primarily Ionotropic: Glycine.
  • Shared Ionotropic and Metabotropic Families:
    • Acetylcholine: $nAChRs$ (ionotropic) vs. $mAChRs$ (metabotropic).
    • GABA: $GABA_A$ (ionotropic) vs. $GABA_B$ (metabotropic).
    • Glutamate: AMPA, Kainate, NMDA (ionotropic) vs. $mGluRs$ (metabotropic).
    • Serotonin ($5\text{-HT}$): $5\text{-HT}_3$ (ionotropic) vs. all other $5\text{-HT}$ subtypes (metabotropic).
    • Purines (ATP): $P2X$ (ionotropic) vs. $P2Y$ and Adenosine receptors (metabotropic).
  • Exclusively Metabotropic:
    • Biogenic amines (Dopamine, Epinephrine, Norepinephrine, Histamine; Serotonin except for $5\text{-HT}_3$).
    • All peptide neurotransmitters.

Molecular Architecture and Activation of G-Protein Coupled Receptors (GPCRs)

• GPCR Structural Organization:
  • Belong to an expansive gene superfamily comprising greater than $1000$ distinct receptor proteins.
  • Consist of a single polypeptide chain configured into $7$ transmembrane-spanning alpha-helices ($H1$ through $H7$).
  • Terminal Orientation:
    • Extracellular amino terminus ($NH_3^+$ / $E1$).
    • Intracellular carboxyl terminus ($COO^-$ / $C4$).
  • Loop Topology:
    • Three extracellular loops: $E2$, $E3$, and $E4$, which help form or constrain ligand-binding pockets.
    • Three intracellular cytoplasmic loops: $C1$, $C2$, and $C3$.
  • Effector and G-Protein Coupling Interface: The second intracellular loop ($C2$), third intracellular loop ($C3$), and the cytoplasmic carboxyl-terminal tail ($C4$) mediate the binding, physical coupling, activation, and structural specificity for heterotrimeric G-proteins.

• Heterotrimeric G-Protein Activation Cycle:
  • The Three Essential Components:
    1. GPCR: Membrane-bound receptor sensor that binds extracellular chemical signaling molecules.
    2. Heterotrimeric G-Protein: Signal transducer composed of alpha ($\alpha$), beta ($\beta$), and gamma ($\gamma$) subunits.
    3. Target / Effector Protein: Downstream enzyme or ion channel regulated by dissociated G-protein subunits.
  • Step-by-Step Activation and Deactivation Mechanism:
    • Basal State: The $\alpha$ subunit is occupied by guanosine diphosphate ($GDP$) and forms a high-affinity heterotrimeric complex with the tightly associated $\beta\gamma$ dimer ($\alpha\beta\gamma\text{-GDP}$).
    • Receptor Activation and Guanine Nucleotide Exchange: Binding of an agonist neurotransmitter triggers a conformational shift in the 7-transmembrane bundle, enabling the intracellular loops to interact with the G-protein. The GPCR acts as a guanine nucleotide exchange factor (GEF), inducing the release of $GDP$ from the $\alpha$ subunit and facilitating the binding of guanosine triphosphate ($GTP$).
    • Heterotrimer Dissociation: Binding of $GTP$ alters the conformation of the $\alpha$ subunit switch regions, causing the functional dissociation of the G-protein into an active $\alpha\text{-GTP}$ monomer and a stable $\beta\gamma$ complex.
    • Effector Interaction: Both the active $\alpha\text{-GTP}$ subunit (belonging to classes $\alpha_s$, $\alpha_i$, or $\alpha_q$) and the dissociated $\beta\gamma$ complex diffuse along the inner leaflet of the plasma membrane to modulate specific effector targets.
    • GTP Hydrolysis and Reassociation: The intrinsic GTPase activity of the $\alpha$ subunit hydrolyzes bound $GTP$ back to $GDP$ and inorganic phosphate ($P_i$). This rate of hydrolysis is significantly accelerated by GTPase-activating proteins ($GAPs$) or the effector itself. Once $GTP$ is hydrolyzed to $GDP$, the $\alpha\text{-GDP}$ subunit rapidly reassociates with the $\beta\gamma$ heterodimer to regenerate the inactive heterotrimer, resetting the cycle.

Canonical G-Protein Effector Cascades

• GPCRs are grouped into three primary functional families based on the functional identity of the alpha subunit ($G\alpha_s$, $G\alpha_q$, $G\alpha_i$):

• $G_s$ Signaling Cascade (Stimulatory):

  • Prototypical Agonist: Norepinephrine.
  • Receptor Archetype: $\beta\text{-adrenergic}$ receptor.
  • Coupled G-Protein: $G_s$ ($\alpha_s$ subunit).
  • Primary Effector: Adenylyl cyclase.
  • Effector Action: Catalyzes the conversion of ATP into cyclic adenosine monophosphate ($cAMP$), increasing intracellular $cAMP$ concentration.
  • Second Messenger: $cAMP$.
  • Later Effector / Protein Kinase: Protein Kinase A (PKA).
  • Downstream Cellular Target Action: PKA phosphorylates specific serine and threonine residues on target enzymes, ion channels, and transcription factors, leading to an overall increase in target protein phosphorylation.

• $G_q$ Signaling Cascade:

  • Prototypical Agonist: Glutamate.
  • Receptor Archetype: Metabotropic glutamate receptor ($mGluR$, Group I).
  • Coupled G-Protein: $G_q$ ($\alpha_q$ subunit).
  • Primary Effector: Phospholipase C ($PLC$).
  • Effector Action: Cleaves membrane phospholipid phosphatidylinositol 4,5-bisphosphate ($PIP_2$) into two distinct second messengers: Diacylglycerol ($DAG$) and Inositol 1,4,5-trisphosphate ($IP_3$).
  • Second Messengers:
    • $DAG$: Lipophilic messenger that remains embedded in the plasma membrane.
    • $IP_3$: Water-soluble messenger that diffuses into the cytoplasm to bind ligand-gated $IP_3$ receptors on the smooth endoplasmic reticulum.
  • Later Effectors / Protein Kinases:
    • Protein Kinase C ($PKC$): Recruited to the membrane and activated by $DAG$ in coordination with calcium.
    • Calcium Release: Mobilization of stored $Ca^{2+}$ from the endoplasmic reticulum lumen into the cytosol.
  • Downstream Cellular Target Action: Increases protein phosphorylation via PKC and activates broad families of intracellular calcium-binding proteins (such as calmodulin and downstream CaMKs).

• $G_i$ Signaling Cascade (Inhibitory):

  • Prototypical Agonist: Dopamine.
  • Receptor Archetype: Dopamine $D_2$ receptor.
  • Coupled G-Protein: $G_i$ ($\alpha_i$ subunit).
  • Primary Effector: Adenylyl cyclase.
  • Effector Action: Direct inhibition of adenylyl cyclase activity, preventing the synthesis of $cAMP$.
  • Second Messenger: Decreased intracellular $cAMP$.
  • Later Effector / Protein Kinase: Decreased activity of Protein Kinase A (PKA).
  • Downstream Cellular Target Action: Leads to a net decrease in target protein phosphorylation, reversing or counteracting the biochemical actions of $G_s$-coupled pathways.

Systematic Diversity of GPCR Classes and Subtypes

• Muscarinic Receptors: Subtypes $M_1$, $M_2$, $M_3$, $M_4$, and $M_5$.
• Metabotropic Glutamate Receptors:
  • Class I: $mGlu_1$, $mGlu_5$.
  • Class II: $mGlu_2$, $mGlu_3$.
  • Class III: $mGlu_4$, $mGlu_6$, $mGlu_7$, $mGlu_8$.
• $GABA_B$ Receptors: Subunits $GABA_{B1}$ and $GABA_{B2}$.
• Dopamine Receptors: Subtypes $D_1$, $D_2$, $D_3$, $D_4$, and $D_5$.
• Adrenergic Receptors:
  • Alpha family: $\alpha_{1A}$, $\alpha_{1B}$, $\alpha_{1D}$, $\alpha_{2A}$, $\alpha_{2B}$, $\alpha_{2C}$.
  • Beta family: $\beta_1$, $\beta_2$, $\beta_3$.
• Histamine Receptors: Subtypes $H_1$, $H_2$, $H_3$, and $H_4$.
• Serotonin Receptors: Subtypes $5\text{-HT}_{1A}$, $5\text{-HT}_{1B}$, $5\text{-HT}_{1D}$, $5\text{-HT}_{1E}$, $5\text{-HT}_{1F}$, $5\text{-HT}_{2A}$, $5\text{-HT}_{2B}$, $5\text{-HT}_{2C}$, $5\text{-HT}_4$, $5\text{-HT}_{5A}$, $5\text{-HT}_6$, and $5\text{-HT}_7$.
• Purinergic GPCRs:
  • Adenosine family: $A_1$, $A_{2A}$, $A_{2B}$, and $A_3$.
  • $P2Y$ family: $P2Y_1$, $P2Y_2$, $P2Y_4$, $P2Y_6$, $P2Y_{11}$, $P2Y_{12}$, $P2Y_{13}$, and $P2Y_{14}$.

Muscarinic Acetylcholine Receptors

• Nomenclature and General Features:
  • Identified by their selective activation by the fungal alkaloid muscarine, derived from the poisonous mushroom Amanita muscaria.
  • Mediate the vast majority of cholinergic actions in the central nervous system, as well as peripheral parasympathetic signaling.

• Subtype Classification and Coupling:
  • Composed of five distinct receptor isoforms divided into two functional classes:
    • $M_1, M_3, M_5$ Subtypes:
      • Coupling: Exclusively couple to $G\alpha_q$.
      • Distribution & Physiology: Distributed throughout the CNS and peripheral nervous system. In the periphery, they mediate smooth muscle contraction and stimulate secretion from exocrine glands via PLC activation and $Ca^{2+}$ mobilization.
    • $M_2, M_4$ Subtypes:
      • Coupling: Exclusively couple to $G\alpha_i$.
      • Distribution & Physiology: Distributed in both the CNS and autonomic control targets. In the heart, $M_2$ receptor activation slows pacemaker frequency and heart rate via inhibition of adenylyl cyclase and opening of inwardly rectifying potassium channels ($GIRK$ channels, mediated by released $\beta\gamma$ subunits).

Metabotropic Glutamate Receptors (mGluRs)

• Structural Architecture:
  • Form obligate homodimers across the plasma membrane.
  • Each monomer features an extracellular "Venus flytrap" ligand-binding domain ($LBD$), linked via a cysteine-rich domain ($CRD$) to the canonical seven-transmembrane domain ($TMD$).
  • Agonist binding closes the Venus flytrap domain around glutamate, inducing structural rearrangements across the dimer interface to activate intracellular G-proteins.

• Functional Groups and Isoforms:

  • Composed of at least $8$ isoforms ($mGluR_1$ through $mGluR_8$) organized into three major functional groups:
    • Group I ($mGluR_1$, $mGluR_5$): Couple to $G\alpha_q$. Stimulate phospholipase C, elevate intracellular $Ca^{2+}$, and play an indispensable role in inducing long-term depression ($LTD$) at synapses in the CA1 region of the hippocampus.
    • Group II ($mGluR_2$, $mGluR_3$): Couple to $G\alpha_i$. Inhibit adenylyl cyclase, suppress $cAMP$ production, and frequently function presynaptically as autoreceptors to reduce transmitter release.
    • Group III ($mGluR_4$, $mGluR_6$, $mGluR_7$, $mGluR_8$): Couple to $G\alpha_i$. Inhibit adenylyl cyclase; $mGluR_6$ is uniquely specialized in retinal ON-bipolar cells.
  • Physiological Roles: Generate slow postsynaptic potentials that can be either excitatory or inhibitory. Many subtypes inhibit voltage-gated $Na^+$ and $Ca^{2+}$ channels.

• Comparative Dynamics: iGluRs versus mGluRs:

*   **Ionotropic Glutamate Receptors ($iGluRs$):**
    *   Mediate rapid synaptic transmission and short-term plasticity, as well as initiating long-term synaptic modifications.
    *   **Temporal Scale:** Channel opening occurs within sub-millisecond ranges ($10^{-4}\text{--}10^{-3}\,s$). AMPA and kainate receptor activation and desensitization operate between $10^{-4}\,s$ and $10^{-1}\,s$, with recovery occurring across $10^{-1}\,s$ to $1\,s$. NMDA receptor gating occurs from $10^{-2}\,s$ to approximately $1\,s$.
*   **Metabotropic Glutamate Receptors ($mGluRs$):**
    *   Mediate slow, sustained modulatory responses and participate in long-term synaptic plasticity.
    *   **Temporal Scale:** G-protein coupling occurs over $10^{-1}\,s$ to $1\,s$. Second messenger and channel modulation operates from $1\,s$ to $10^2\,s$. Arrestin recruitment and kinase cascades proceed from $1\,s$ to $10^3\,s$. Receptor trafficking and downstream translational/transcriptional changes persist from $10^2\,s$ to $10^4\,s$ and beyond.

Metabotropic GABA_B Receptors

• Obligate Heterodimeric Architecture:
  • Functional $GABA_B$ receptors do not assemble as homomers; they are obligate heterodimers composed of two distinct subunits: $GABA_{B1}$ and $GABA_{B2}$.
  • Functional Specialization of Subunits:
    • $GABA_{B1}$: Contains the extracellular Venus flytrap domain that contains the orthosteric binding site for GABA.
    • $GABA_{B2}$: Contains the 7-transmembrane domain that physically interacts with and activates the heterotrimeric G-protein ($G\alpha_{i/o}$).
  • Cytoplasmic Anchoring: The intracellular carboxyl tails assemble with protein scaffolds, interacting with cell adhesion molecules, trafficking proteins, transcription factors, and $\beta\text{-filamin}$, which links the receptor complex to the actin microfilament cytoskeleton.

• Localization and Inhibitory Mechanism:
  • Located throughout the CNS and autonomic control centers, frequently co-localizing postsynaptically and presynaptically with ionotropic $GABA_A$ receptors.
  • Inhibitory Signaling via $G\alpha_{i/o}$:
    • Potassium Channel Activation: Dissociated $\beta\gamma$ subunits bind directly to G-protein-coupled inwardly rectifying potassium channels ($GIRK$), increasing $K^+$ efflux and causing long-lasting membrane hyperpolarization.
    • Calcium Channel Inhibition: Dissociated $\beta\gamma$ subunits directly block voltage-gated calcium channels ($P/Q$- and $N$-type $Ca^{2+}$ channels), preventing presynaptic $Ca^{2+}$ influx and inhibiting neurotransmitter exocytosis.
    • Adenylyl Cyclase Inhibition: The $G\alpha_{i/o}$ subunit inhibits adenylyl cyclase, depressing intracellular $cAMP$ production and reducing action potential frequency.

Biogenic Amine Systems

• Overview of Biogenic Amines:
  • Regulate fundamental CNS and PNS behaviors including arousal, attention, motor control, mood, and homeostatic vegetative functions.
  • Central targets in neuropharmacology and modern psychiatric therapeutics.
  • Composed of three chemical subclasses:
    1. Catecholamines: Dopamine, Norepinephrine, Epinephrine (contain a catechol core: a benzene ring with two adjacent hydroxyl groups and an attached ethylamine side chain).
    2. Indoleamine: Serotonin ($5\text{-hydroxytryptamine}$ / $5\text{-HT}$).
    3. Imidazoleamine: Histamine.

• Catecholamine Biosynthesis:
  • Synthesized through a sequential enzymatic pathway starting from the essential amino acid tyrosine:
    1. Tyrosine Hydroxylase ($TH$): Hydroxylates Tyrosine to form Dihydroxyphenylalanine ($\text{DOPA}$) using molecular oxygen ($O_2$). This is the rate-limiting step in catecholamine synthesis.
    2. DOPA Decarboxylase: Removes the carboxyl group ($-COO^-$) from DOPA, releasing carbon dioxide ($CO_2$) to synthesize Dopamine.
    3. Dopamine-$\beta$ Hydroxylase ($DBH$): Hydroxylates the beta-carbon of dopamine using molecular oxygen ($O_2$) to synthesize Norepinephrine.
    4. Phenylethanolamine $N$-Methyltransferase ($PNMT$): Transfers a methyl group from an $S$-adenosylmethionine donor ($R\text{-}CH_3 \rightarrow R$) to the primary amine of norepinephrine to form Epinephrine.

• Dopamine Receptors:

  • Concentrated heavily within the striatum (regulating motor initiation and execution), as well as mesolimbic pathways mediating motivation and reward.
  • Every dopamine receptor is metabotropic; no ionotropic dopamine receptors exist.
  • Composed of $5$ subtypes categorized into two families:
    • $D_1\text{-like}$ Family ($D_1$ and $D_5$): Couple to $G\alpha_s$, stimulating adenylyl cyclase and increasing $cAMP$.
    • $D_2\text{-like}$ Family ($D_2$, $D_3$, and $D_4$): Couple to $G\alpha_i$, inhibiting adenylyl cyclase, lowering $cAMP$, and enhancing potassium conductance.

• Adrenergic Receptors:

  • Both norepinephrine and epinephrine act on alpha ($\alpha$) and beta ($\beta$) adrenergic receptors.
  • All adrenergic receptors are GPCRs.

*   **Three Main Families and Subclasses:**
    *   **$\alpha_1$ Adrenergic Receptors ($\alpha_{1A}$, $\alpha_{1B}$, $\alpha_{1D}$):**
        *   **Coupling:** Exclusively couple to $G\alpha_q$.
        *   **Distribution:** Localized on sympathetic postganglionic target neurons, cardiac tissue, and the hippocampus.
        *   **Mechanism:** Activate PLC, increasing intracellular $Ca^{2+}$ to mediate vasoconstriction and neuronal depolarization.
    *   **$\alpha_2$ Adrenergic Receptors ($\alpha_{2A}$, $\alpha_{2B}$, $\alpha_{2C}$):**
        *   **Coupling:** Exclusively couple to $G\alpha_i$.
        *   **Distribution:** Located in sympathetic neurons, central adrenergic neurons, and the heart.
        *   **Mechanism:** Inhibit adenylyl cyclase; often act as presynaptic auto- or heteroreceptors that suppress further norepinephrine release.
    *   **$\beta$ Adrenergic Receptors ($\beta_1$, $\beta_2$, $\beta_3$):**
        *   **Coupling:** Exclusively couple to $G\alpha_s$.
        *   **Distribution:** Expressed in sympathetic target targets, cardiac muscle ($\beta_1$), and central regions such as the caudate nucleus.
        *   **Mechanism:** Stimulate adenylyl cyclase, elevating $cAMP$ and activating PKA (e.g., increasing heart rate and myocardial contractility).

• Histamine Receptors:

  • Produced by neurons localized in the tuberomammillary nucleus of the hypothalamus with projections throughout the neuroaxis.
  • Mediate central arousal, vigilance, and cognitive attention.
  • All four receptor subtypes ($H_1$, $H_2$, $H_3$, $H_4$) are metabotropic GPCRs.
  • Pharmacological & Physiological Roles:
    • $H_1$ receptor activation is implicated in vestibular and motion sickness pathways (antagonists serve as anti-emetics and motion-sickness medications).
    • $H_2$ receptor activation stimulates gastric acid secretion in parietal cells of the stomach (antagonists serve as antacids).

• Serotonin ($5\text{-HT}$) Receptors:

  • Synthesized from tryptophan by neurons clustered within the brainstem raphe nuclei, which provide diffuse projections throughout the forebrain, cerebellum, and spinal cord to regulate mood, sleep-wake cycles, and circadian rhythmicity.
  • Displays broad receptor heterogeneity ($5\text{-HT}_1$ through $5\text{-HT}_7$).
  • Critical Structural Divergence:
    • $5\text{-HT}_3$ Receptor: The sole ionotropic serotonin receptor (a non-selective cation channel).
    • All Other Serotonin Receptors ($5\text{-HT}_1$, $5\text{-HT}_2$, $5\text{-HT}_4$, $5\text{-HT}_5$, $5\text{-HT}_6$, $5\text{-HT}_7$): Metabotropic GPCRs coupled to diverse G-proteins ($G\alpha_i$, $G\alpha_q$, or $G\alpha_s$).
  • Hallucinogenic compounds such as Lysergic Acid Diethylamide (LSD) act via metabotropic serotonin receptors (specifically targeting the $5\text{-HT}_{2A}$ subtype).

Purinergic and Neuropeptide Receptor Systems

• Purinergic Neurotransmission:
  • ATP is stored inside virtually all synaptic vesicles alongside classical neurotransmitters and functions as an excitatory co-transmitter in the spinal cord, central synapses, and autonomic ganglia.
  • Extracellular ATP is enzymatically degraded by ecto-nucleotidases into adenosine. While adenosine is a critical signaling molecule, it is not packaged into vesicles and is technically not classified as a classical neurotransmitter.
  • Purinergic Receptor Classification:
    1. $P2X$ Receptors: Ionotropic, ATP-gated non-selective cation channels that mediate fast depolarization.
    2. $P2Y$ Receptors ($P2Y_1$ to $P2Y_{14}$): Metabotropic GPCRs activated by purine nucleotides (ATP, ADP, UTP).
    3. Adenosine Receptors ($A_1$, $A_{2A}$, $A_{2B}$, $A_3$): Metabotropic GPCRs activated selectively by adenosine.

• Neuropeptides and Their Receptors:
  • Every neuropeptide receptor identified is a metabotropic GPCR.
  • Neuropeptides function at very low nanomolar concentrations and can act over distances far removed from their initial release sites via volume transmission.

*   **Major Classes of Neuropeptides:**
    *   **Brain-Gut Peptides:** Substance P ($11$ amino acids), Cholecystokinin octapeptide (CCK-8, $8$ amino acids), Vasoactive intestinal peptide (VIP, $28$ amino acids).
    *   **Opioid Peptides:** Leucine enkephalin ($5$ amino acids), $\alpha\text{-Endorphin}$ ($16$ amino acids), Dynorphin A ($17$ amino acids).
    *   **Pituitary Peptides:** Vasopressin ($9$ amino acids), Oxytocin ($9$ amino acids), Adrenocorticotropic hormone (ACTH, $39$ amino acids).
    *   **Hypothalamic-Releasing Peptides:** Thyrotropin-releasing hormone (TRH, $3$ amino acids), Luteinizing hormone-releasing hormone (LHRH, $10$ amino acids), Somatostatin 14 ($14$ amino acids).
    *   **Miscellaneous Peptides:** Angiotensin II ($8$ amino acids), Neuropeptide Y ($36$ amino acids), Neurotensin ($13$ amino acids).

• Opioid Receptors:
  • Subtypes: Three primary receptor classes: Mu ($\mu$ / MOR), Kappa ($\kappa$ / KOR), and Delta ($\delta$ / DOR).
  • Coupling: Primarily couple to $G\alpha_i$ and $G\alpha_q$.
  • Distribution: Mu opioid receptors (MOR) are the most broadly distributed throughout both the CNS and PNS.
  • Analgesic Mechanism: Opioid receptor activation suppresses presynaptic $Ca^{2+}$ channel conductance (preventing neurotransmitter release from nociceptors) and opens postsynaptic $K^+$ channels (hyperpolarizing pain-transmission neurons).
  • Endogenous Agonists: Enkephalins, endorphins, and dynorphins.
  • Exogenous Agonist Source: Opiates derived from the latex of the opium poppy (Papaver somniferum).

• Cannabinoid Receptors:
  • Subtypes: Two known receptors: $CB_1$ (predominantly central nervous system) and $CB_2$ (predominantly immune cells and peripheral tissues).
  • Coupling: Both subtypes couple to $G\alpha_i$.
  • Endogenous Agonists (Endocannabinoids): Anandamide and 2-arachidonoylglycerol (2-AG).
  • Exogenous Source: Phytocannabinoids derived from Cannabis sativa.

Core Principles of Metabotropic Receptor Function

• Dual Mode of Synaptic Action:
  1. Mediation of Slow Synaptic Transmission: Direct G-protein subunit modulation of ion channels alters membrane excitability over long timescales.
  2. Modulation of Fast Synaptic Transmission: Intracellular second-messenger and phosphorylation cascades modulate ionotropic receptor sensitivity, presynaptic vesicle fusion machinery, and postsynaptic scaffolding.
• Structural Conservation: All GPCRs share a 7-transmembrane alpha-helical structural core that couples an extracellular ligand-binding event to an intracellular interaction with a soluble heterotrimeric G-protein.
• Dimeric Architecture Specificity: Glutamate ($mGluRs$) and GABA ($GABA_B$) receptors are unique among neurotransmitter GPCRs in functioning as obligate dimers possessing specialized extracellular "Venus flytrap" domains.
• Functional Diversity: The functional divergence across GPCR systems is generated by combinatorially coupling varied receptor isoforms to distinct heterotrimeric G-protein subunits ($\alpha_s$, $\alpha_i$, $\alpha_q$) and downstream effectors.

Questions & Discussion

• Question: Do metabotropic receptors bind their signaling partner at the extracellular domains?
  • Answer: True. The ligand (neurotransmitter) binds to extracellular domains or within a pocket defined by the extracellular loops and transmembrane regions.
• Question: Do metabotropic receptors lead to changes in postsynaptic potential?
  • Answer: True. Metabotropic receptor cascades alter postsynaptic potential indirectly by opening or closing ion channels (e.g., $GIRK$ channels, calcium channels) through G-protein subunits or phosphorylation cascades.
• Question: Can only ionotropic receptors be inhibitory, while metabotropic receptors are always excitatory?
  • Answer: False. Many metabotropic receptors couple to $G\alpha_i$ (e.g., $GABA_B$, $D_2$, $\alpha_2$, $mGluR_{2\text{--}8}$, and opioid receptors), which decrease $cAMP$, open $K^+$ channels, and inhibit $Ca^{2+}$ channels, producing profound postsynaptic and presynaptic inhibition.